Scholars@Duke
Rhonda L Bitting

Rhonda L Bitting

Associate Professor of Medicine
Medicine, Medical Oncology
rhonda.bitting@duke.edu
DUMC Box 103861, Durham, NC 27710
905 S LaSalle St, Rm 2052, Durham, NC 27710

Scholarly Works - Conferences

Patterns of poly(ADP-ribose) polymerase inhibitor use and overall survival in United States veterans with prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2026 e17049Background: PARP inhibitors (PARPi) are life-prolonging therapies for men with ... Full text Cite

Analysis of genomic and clinical predictors of overall survival and PSA response: Results from the PRECISION registry.

Conference Journal of Clinical Oncology · June 1, 2026 5051Background: Outcomes in advanced prostate cancer vary substantially according to ... Full text Cite

STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.

Conference Journal of Clinical Oncology · June 1, 2026 5106Background: Current trials use prostate-specific antigen (PSA) response of ≤0.2 n ... Full text Cite

Sequencing of PARP inhibitors and taxane chemotherapy in HRR-altered metastatic castration-resistant prostate cancer: A real-world VA analysis.

Conference Journal of Clinical Oncology · June 1, 2026 5072Background: Taxane-based chemotherapy (taxane) and poly(ADP-ribose) polymerase in ... Full text Cite

SPOP mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI).

Conference Journal of Clinical Oncology · June 2025 e17082Background: Inactivating missense mutations in the tumor suppressor gene speckle-type pox virus and zinc finger protein ... Full text Cite

Pilot study of a muscadine grape extract supplement to decrease fatigue among older cancer survivors.

Conference Journal of Clinical Oncology · June 2025 12057Background: Fatigue is a prevalent symptom among older cancer survivors and is associated with declines in physical func ... Full text Cite

Abstract CT254: Veterans Affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligometastatic prostate cancer (VA STARPORT)

Conference Cancer Research · April 25, 2025 AbstractPurpose/Objective(s):The concept of metastasis-directed therapy (MDT) using radiotherapy (RT) or surgery for oligometastatic ( ... Full text Cite

Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 10, 2025 154Background: In 2004, docetaxel (DOC), a semi-synthetic taxane, received regulatory approval for mCRPC based on improved ov ... Full text Cite

Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Conference Journal of Clinical Oncology · June 1, 2023 5016 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. For high risk PSA recurrence, current standard ADT duration is up to 2 years with RT; shortening but intensifying systemic therapy may i ... Full text Cite

Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.

Conference Journal of Clinical Oncology · May 20, 2021 e17033 Background: PARP inhibitors (PARPis) were approved by the FDA for the treatment of advanced prostate cancer (PC) among patients (pts) harboring mutations in genes responsible for homologous DNA repair. Increasing evidence ... Full text Cite

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Conference Journal of Clinical Oncology · February 20, 2021 90 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. Current standard duration of ADT for high risk PSA recurrence is up to 2 years with RT; therefore shortening but intensifying systemic the ... Full text Cite

Single-arm phase II study of low-dose paclitaxel and pembrolizumab in platinum-refractory metastatic urothelial carcinoma (UC).

Conference Journal of Clinical Oncology · February 20, 2021 433 Background: Single agent checkpoint inhibition is effective in a small proportion of platinum-refractory UC patients but improvements are needed. UC is highly inflammatory, and low-dose chemotherapy may enhance the response t ... Full text Cite

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Conference Journal of Clinical Oncology · May 20, 2019 TPS5097 Background: Androgen deprivation combined with salvage external beam radiation therapy (RT) have improved survival for patients (pts) with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP ... Full text Cite

Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.

Conference Journal of Clinical Oncology · March 1, 2019 29 Background: Salvage external beam radiotherapy (RT) and hormonal therapy improves survival over RT alone in men with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP). We investigated the safe ... Full text Cite

Phase I study of muscadine grape extract in advanced malignancy.

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Conference Eur J Cancer · August 2017 BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single ar ... Full text Link to item Cite

Abstract 3187: Role of exosome secretion in the survival of enzalutamide-resistant prostate cancer cells: Syntaxin 6 as a novel therapeutic target

Conference Cancer Research · July 1, 2017 AbstractProstate cancer (PCa) is the most commonly diagnosed malignancy in the United States and remains the second leading cause of cancer deaths among American men. PCa deaths are typically the result of m ... Full text Cite

A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.

Conference Journal of Clinical Oncology · May 20, 2017 TPS2616 Background: FGFR inhibition is a promising and clinically proven therapeutic approach in a number of solid tumors where genetic alterations of FGFR drive oncogenesis. PRN1371 is a highly selective oral, irreversible inhib ... Full text Cite

Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.

Conference Journal of Clinical Oncology · February 1, 2014 178 Background: Serum alkaline phosphatase (AP) changes in men with metastatic prostate cancer have been described since the Nobel Prize winning discovery of the hormonal dependence of PC. High serum AP is independently associate ... Full text Cite

Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.

Conference Journal of Clinical Oncology · February 1, 2014 65 Background: Given the evolving treatments available in metastatic castration resistant prostate cancer (mCRPC), predictive biomarkers are desirable that maximize benefit and minimize harms and costs.The goal of this study was ... Full text Cite

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2013 105 Background: PTEN loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 Kinase pathway. Temsirolimus blocks mTOR/TORC1, a key signaling node in this pathway; its activity in men with advance ... Full text Cite

Abstract P4-06-07: Isoform specific antibodies against the fibroblast growth factor receptor 2 have predictive and therapeutic implications in the treatment of human breast cancers

Conference Cancer Research · December 15, 2012 AbstractBackground: Aberrant induction of the epithelial to mesenchymal transition cascade (EMT) has a defining role in shaping cancer malignancy. Despite the complexity of this process, the alternative spli ... Full text Cite